Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

被引：0
作者：
T. Masuda
H. Imai
T. Kuwako
Y. Miura
R. Yoshino
K. Kaira
K. Shimizu
N. Sunaga
Y. Tomizawa
S. Ishihara
A. Mogi
T. Hisada
K. Minato
A. Takise
R. Saito
M. Yamada
机构：
[1] Gunma University Graduate School of Medicine,Department of Medicine and Molecular Science
[2] Gunma Prefectural Cancer Center,Department of Respiratory Medicine
[3] National Hospital Organization Nishigunma Hospital,Division of Respiratory Medicine
[4] Gunma University Graduate School of Medicine,Department of Oncology Clinical Development
[5] Gunma University Graduate School of Medicine,Department of Thoracic and Visceral Organ Surgery
[6] Isesaki Municipal Hospital,Division of Internal Medicine
[7] Gunma University Graduate School of Medicine,Department of General Surgical Science
[8] Maebashi Red Cross Hospital,Division of Respiratory Medicine
来源：
Clinical and Translational Oncology | 2015年 / 17卷
关键词：
Advanced non-small cell lung cancer; mutations; Gefitinib; Non-small cell lung cancer; Second-line platinum-based chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：702 / 709
页数：7
相关论文
共 196 条
[1]  
Siegel R(2012)Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 220-241
[2]  
DeSantis C(1995)Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 899-909
[3]  
Virgo K(2004)American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol. 22 330-353
[4]  
Stein K(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[5]  
Mariotto A(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol. 11 121-128
[6]  
Smith T(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[7]  
Pfister DG(2009)First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 1394-1400
[8]  
Johnson DH(2009)Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations Clin Cancer Res 15 4493-4498
[9]  
Azzoli CG(2012)First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol. 30 1122-1128
[10]  
Sause W(2014)Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene J Clin Oncol 2 731-736
12345678910